Marketable Securities, Current in USD of AVADEL PHARMACEUTICALS PLC from Q4 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of investment in marketable security, classified as current.
Summary
AVADEL PHARMACEUTICALS PLC quarterly Marketable Securities, Current history and change rate from Q4 2010 to Q3 2025.
  • AVADEL PHARMACEUTICALS PLC Marketable Securities, Current for the quarter ending 30 Sep 2025 was $11.8M, a 68.4% decline year-over-year.
Marketable Securities, Current, Quarterly (USD)
Marketable Securities, Current, YoY Quarterly Change (%)

AVADEL PHARMACEUTICALS PLC Quarterly Marketable Securities, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $11.8M -$25.5M -68.4% 30 Sep 2025 10-Q 04 Nov 2025
Q2 2025 $18.1M -$24.4M -57.3% 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 $10.1M -$42.9M -80.9% 31 Mar 2025 10-Q 07 May 2025
Q4 2024 $22.4M -$51.5M -69.7% 31 Dec 2024 10-Q 04 Nov 2025
Q3 2024 $37.2M -$64.1M -63.3% 30 Sep 2024 10-Q 12 Nov 2024
Q2 2024 $42.5M -$68M -61.5% 30 Jun 2024 10-Q 08 Aug 2024
Q1 2024 $53M +$35.5M +202% 31 Mar 2024 10-Q 08 May 2024
Q4 2023 $73.9M +$51.4M +228% 31 Dec 2023 10-K 03 Mar 2025
Q3 2023 $101M +$55.6M +122% 30 Sep 2023 10-Q 08 Nov 2023
Q2 2023 $111M +$60.5M +121% 30 Jun 2023 10-Q 09 Aug 2023
Q1 2023 $17.5M -$45.1M -72% 31 Mar 2023 10-Q 04 May 2023
Q4 2022 $22.5M -$84M -78.9% 31 Dec 2022 10-K 29 Feb 2024
Q3 2022 $45.8M -$77.2M -62.8% 30 Sep 2022 10-Q 09 Nov 2022
Q2 2022 $50M -$85.7M -63.2% 30 Jun 2022 10-Q 09 Aug 2022
Q1 2022 $62.6M -$83.2M -57.1% 31 Mar 2022 10-Q 09 May 2022
Q4 2021 $107M -$43.2M -28.8% 31 Dec 2021 10-K 29 Mar 2023
Q3 2021 $123M -$25.5M -17.2% 30 Sep 2021 10-Q 08 Nov 2021
Q2 2021 $136M -$679K -0.5% 30 Jun 2021 10-Q 09 Aug 2021
Q1 2021 $146M +$106M +265% 31 Mar 2021 10-Q 10 May 2021
Q4 2020 $150M +$95.3M +175% 31 Dec 2020 10-K 16 Mar 2022
Q3 2020 $148M +$88.9M +149% 30 Sep 2020 10-Q 09 Nov 2020
Q2 2020 $136M +$74.2M +119% 30 Jun 2020 10-Q 10 Aug 2020
Q1 2020 $40M -$30.2M -43.1% 31 Mar 2020 10-Q 11 May 2020
Q4 2019 $54.4M -$36.2M -40% 31 Dec 2019 10-K 09 Mar 2021
Q3 2019 $59.6M -$47.8M -44.5% 30 Sep 2019 10-Q 12 Nov 2019
Q2 2019 $62.2M -$72.5M -53.8% 30 Jun 2019 10-Q 09 Aug 2019
Q1 2019 $70.2M -$87M -55.4% 31 Mar 2019 10-Q 08 May 2019
Q4 2018 $90.6M +$13.1M +16.9% 31 Dec 2018 10-K 16 Mar 2020
Q3 2018 $107M +$29.3M +37.4% 30 Sep 2018 10-Q 05 Nov 2018
Q2 2018 $135M +$4.34M +3.33% 30 Jun 2018 10-Q 07 Aug 2018
Q1 2018 $157M +$10.3M +7% 31 Mar 2018 10-Q 04 May 2018
Q4 2017 $77.5M -$37.5M -32.6% 31 Dec 2017 10-K 15 Mar 2019
Q3 2017 $78.2M -$52.7M -40.3% 30 Sep 2017 10-Q 09 Nov 2017
Q2 2017 $130M -$674K -0.52% 30 Jun 2017 10-Q 09 Aug 2017
Q1 2017 $147M +$24.9M +20.4% 31 Mar 2017 10-Q 10 May 2017
Q4 2016 $115M +$35.2M +44.2% 31 Dec 2016 10-K 16 Mar 2018
Q3 2016 $131M 30 Sep 2016 10-Q 14 Nov 2016
Q2 2016 $131M +$70.1M +115% 30 Jun 2016 10-Q 15 Aug 2016
Q1 2016 $122M +$47.4M +63.6% 31 Mar 2016 10-Q 10 May 2016
Q4 2015 $79.7M +$26.7M +50.2% 31 Dec 2015 10-K 28 Mar 2017
Q2 2015 $60.9M +$37.1M +156% 30 Jun 2015 6-K 31 Dec 2015
Q1 2015 $74.6M +$46.6M +166% 31 Mar 2015 6-K 10 Jul 2015
Q4 2014 $53.1M +$52.7M +13135% 31 Dec 2014 10-K 15 Mar 2016
Q3 2014 $52.5M +$51M +3464% 30 Sep 2014 6-K 17 Nov 2014
Q2 2014 $23.8M +$22.4M +1613% 30 Jun 2014 6-K 08 Aug 2014
Q1 2014 $28M 31 Mar 2014 6-K 08 Jul 2014
Q4 2013 $401K -$6.01M -93.7% 31 Dec 2013 20-F 01 Oct 2015
Q3 2013 $1.47M 30 Sep 2013 6-K 15 Jan 2014
Q2 2013 $1.39M -$14.3M -91.2% 30 Jun 2013 6-K 06 Dec 2013
Q4 2012 $6.41M -$14.6M -69.5% 31 Dec 2012 20-F 01 Oct 2015
Q2 2012 $15.7M 30 Jun 2012 6-K 14 Dec 2012
Q1 2012 $18.4M 31 Mar 2012 6-K 13 Sep 2012
Q4 2011 $21M -$2.12M -9.17% 31 Dec 2011 20-F/A 30 Apr 2014
Q4 2010 $23.2M 31 Dec 2010 20-F 30 Apr 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.